Articles related to HEALTH OUTCOMES

Worldwide mortality from sepsis decreased by approximately 50% between 1990 and 2017, yet the condition remains the most expensive cause of hospitalization in the United States.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

A multicenter trial of 7,062 post-MI patients found that colchicine therapy, despite reducing C-reactive protein levels by 1.28 mg/L, did not significantly impact the composite outcome of cardiovascular death, recurrent MI, stroke, or unplanned revascularization over 3 years of follow-up.

A multicenter trial reports that adding middle meningeal artery embolization to surgical evacuation reduced reoperation rates from 11.3% to 4.1% in subdural hematoma patients, though further safety evaluation is needed.

In patients with heart failure and preserved ejection fraction, finerenone demonstrated a 16% reduction in the primary composite endpoint of total worsening heart failure events and cardiovascular death compared to placebo.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.